WaveMan
WaveMan · Company
VTVT · Vtv Therapeutics Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

VTVT vTv Therapeutics (VTVT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001641489
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
23
13F, latest reported quarter

vTv Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for vTv Therapeutics Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
SEKHRI PAUL J
Pres, CEO and Exec Chairperson
BUY
2024-11-19 SECtraded 2024-11-18
1,844
$31.3K
+66.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Nov 15, 2024.
  • The trade is 36.9% of the 5,000 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres, CEO and Exec Chairperson SEKHRI PAUL J bought about $31.3K of VTVT on Nov 18, 2024, the largest insider purchase at the company since 2022; 23 funds added in the latest 13F quarter.
SEKHRI PAUL J
Pres, CEO and Exec Chairperson
BUY
2024-11-19 SECtraded 2024-11-15
1,778
$30.0K
+66.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 56.3% of the 3,156 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres, CEO and Exec Chairperson SEKHRI PAUL J bought about $30.0K of VTVT on Nov 15, 2024, the largest insider purchase at the company since 2022; 23 funds added in the latest 13F quarter.
SEKHRI PAUL J
Pres, CEO and Exec Chairperson
BUY
2024-11-19 SECtraded 2024-11-15
1,378
$22.5K
+66.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 1,378 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres, CEO and Exec Chairperson SEKHRI PAUL J bought about $22.5K of VTVT on Nov 15, 2024, the largest insider purchase at the company since 2022; 23 funds added in the latest 13F quarter.
FRY JOHN A
Director
BUY
2022-11-30 SECtraded 2022-11-29
40,461
$33.6K
-25.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 28, 2022.
  • The trade is 66.3% of the 61,000 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FRY JOHN A bought about $33.6K of VTVT on Nov 29, 2022, the largest insider purchase at the company on our record; 23 funds added in the latest 13F quarter.
FRY JOHN A
Director
BUY
2022-11-30 SECtraded 2022-11-28
20,539
$17.0K
-25.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 20,539 shares held after it.
  • No other insider bought within 30 days.
  • 23 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director FRY JOHN A bought about $17.0K of VTVT on Nov 28, 2022, the largest insider purchase at the company on our record; 23 funds added in the latest 13F quarter.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
23 funds bought in last quarter
below 66% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.6% of the float short (float per yahoo 2026-10-27) · 5.7 days to cover · settled 2026-10-15
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch VTVT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+23.4%12M
+0%+35%+70%+105%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns VTVT: institutional holders (13F)

13F holdings, latest reported quarter
SAMSARA BIOCAPITAL, LLC
298,496 sh
$11.2M
MILLENNIUM MANAGEMENT LLC
269,874 sh
$10.2M
FMR LLC
260,391 sh
$9.8M
Siren, L.L.C.
163,000 sh
$6.1M
BAKER BROS. ADVISORS LP
148,314 sh
$5.6M

Congress trades in VTVT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

VTVT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

VTVT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Biotechnology Portfolio
$8.7M position · as of 2026-05-31
0.2%
iShares Micro-Cap ETF
$272.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$18.3K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$1.2M position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$491.3K position · as of 2026-05-31
0.0%
Victory Extended Market Index Fund
$7.6K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 2
1 active
1
Phase 3
1 active
1
Multi-phase
0 active
What changed recently
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who
2026-09-22 · Completion moved 2027-04 → 2027-06
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 23 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

VTVT financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$36.8M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-12.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.07x
long-term 2019-12-31 (79 months older than the period end) plus current 2021-12-31 (54 months older than the period end); equity 2026-06-30
Cash flow to debt
-3.16x
TTM operating cash flow over long-term 2019-12-31 (79 months older than the period end) plus current 2021-12-31 (54 months older than the period end)
Return on equity
-11.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-8.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-18.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$1.0M$0$2.0M
Operating income-$32.8M-$24.2M-$25.5M-$22.5M
Net income-$27.0M-$18.5M-$20.2M-$19.2M
Operating cash flow-$25.3M-$25.3M-$19.1M-$16.0M
Cash$88.9M$36.7M$9.4M$12.1M
SEC XBRL, fiscal years, as known on 2026-10-28

VTVT Stock Sonar score 5/7 axes

Find similar shapesCompare

VTVT ranks highest on profitability (75th percentile) and risk and compliance (62nd), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
75
Inputs
  • Return on equity-11.7% · 75 pct, sector of 545
  • Return on assets-8.3% · 76 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-18.2% · 74 pct, sector of 576
Financial health
48
Inputs
  • Debt to equity0.07x · 59 pct, sector of 352
  • Cash flow to debt-3.16x · 37 pct, sector of 371
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
34
Inputs
  • Funds adding, latest quarter23 · 34 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
62
Inputs
  • Short interest, % of float+6.6% · 51 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.8% · 73 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies